GH Research Reports Third Quarter 2026 Financial Results and Provides Business Update

GH Research PLC (GHRS) — Novel GH001 Aerosol Delivery System (ADS) device: final results of the GH001-HV-106 trial support going from 3 → 1 doses per treatment visitTRD pivotal program — positive initial feedback from FDA, End-of-Phase 2 meeting expected in Q1 2027, initiation shortly afterPPD pivotal program — initiation targeted for H2 2027Vanina Popova, MD, appointed Chief Development Officer — Formerly Clinical Development at J&J, lead author of pivotal Spravato® trial publicationCash, cash equivalents and marketabl

Source: GlobeNewswire — read the full announcement there.

See our GH Research company profile for background, links, and more GH Research news.